Community post

US biotech company Felix Biotechnology announced the initiation of its first clinical trial, CYPHY, a phase 1/2 single center trial that will test its first targeted phage therapy candidate, YPT-01, against chronic P. aeruginosa infections in cystic fibrosis. The trial will take place at Yale University.